Drug intelligence / Profile preview

Listeria-TT

Development stage: Preclinical
Lead developer: Loki Therapeutics
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
Administration: Intravenous, Intraperitoneal

Overview

Listeria-TT is an investigational immunotherapy platform developed by Loki Therapeutics in collaboration with the Albert Einstein College of Medicine. It utilizes a live-attenuated strain of *Listeria monocytogenes* as a bacterial vector to deliver the tetanus toxoid (TT) protein directly into tumor cells and the tumor microenvironment. The therapeutic strategy is based on "recall antigen" technology, which leverages the fact that most individuals have been previously vaccinated against tetanus and possess circulating memory T cells specific to the TT protein. By delivering and expressing the TT antigen within the immunosuppressive tumor microenvironment, Listeria-TT reactivates these pre-existing memory T cells to recognize and destroy the infected cancer cells. This approach is primarily being developed for the treatment of advanced solid tumors, with a significant focus on pancreatic cancer.

Other names: Listeria-Recall Antigen Technology

Targets

TT-MHC-II (Tetanus toxoid-derived peptides presented on MHC class II on infected tumor cells)Listeria monocytogenes

Beyond the preview

Go deeper on Listeria-TT.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Listeria-TT.

Explore the full profile